6.3.b. Bibliografia. Coagulacion intravascular diseminada

Capítulo 6. 3. Coagulación Intravascular Diseminada

Bibliografía

1. Cabrer B, Mut A, Villalonga C, Vidal R, Orriols J, y Siquier B. Coagulación intravascular diseminada. Jano 1982; 501: 15-50.
2. Williams EC. and Mosher DF. Disseminated intravascular coagulation.
In: Hoffman R, Benz Jr EJ, Shattil SJ, Fuise B, Cohen HJ, Silberstein LE.Eds. Hematology: Basic principles and practice. (2.ª ed). New York. Churchill Livingstone 1995; 1758-1769.
3. Wolf PL. The importance of a2-Antiplasmin in the defribrination
syndrome. Arch Intern Med 1989; 149: 1724-1725.
4. Bick RL. Disseminated intravascular coagulation. Hematol/Oncol Clin
North Am. 1992; 6: 1259-1285.
5. Risberg B, Andreasson S, and Erisksson E. Disseminated intravascular
coagulation. Act Anesth Scand. 1991; 35: 60-71.
6. Hardaway RM, Williams CH, Sun Y. A new approach to the treatment of experimental septic shock. J Surg Res. 1996, 61: 311-316.
7. Seligsohn U. Disseminated intravascular coagulation. In: Beutler E,
Lichtman MA, Coller BS, Kipps TJ. Eds Hematology. (Fith ed) New York. Mac Graw Hill. 1995; 1947-1516.
8. Minna JD, Robboy SJ, Colman RW. Disseminated intravascular
coagulation in man. Charles C Thomas. Springfield IL 1974.
9. Castillo S. Alteraciones de la hemostasia. En Ginestal R. Ed. Cuidados
Intensivos. Madrid. Ed Aran. 1991; 955-972.
10. Nanfro JJ. Anticoagulants in critical care medicine. In: Chernow B Ed. The Pharmacology approach to the criticaly ill patients. Baltimore.Williams & Wilkins. 1994; 666-684.
11. Csako G, Suba E, Elin RJ. Endotoxin-induced platelet activation in human
whole bood in vitro. Thromb Haemostas 1988; 59: 378-382.
12. Burhop KE, Van der Zee H, Bizios R, Kaplan JE, Malik AB. Pulmonary
vascular responses to platelet-activating factor in awake sheep and the role
of cyclooxygenase metabolites. Am Rev Respir Dis. 1986; 134: 548-554.
13. Ansell JE. Acquired bleeding disorders. In: Rippe JM, Irwin RS, Fink MP
and Cerra FB. Eds. Intensive Care Medicine 3.ª Ed. Boston. Little Brown.
1996; 1357-1399.
14. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
15. Velasco F, Torres A, Guerrero A, Andrés P, Guerrero R, Aljama P. Behaviour of the contact phase of blood coagulation in the adult respiratory distress syndrome (ARDS). Thromb Haemostas 1986; 55: 357-360.
16. Herrera C, Velasco F, Guerrero R, Álvarez F, and Torres A. Contact phase of blood coagulation in cardiogenic pulmonary oedema (CPO) and adult respiratory distress syndrome (ARDS). Intens Care Med 1989; 15: 99-104.
17. Guerrero R, Velasco F, Rodríguez M, López A, Rojas R, Álvarez MA, et al. Endotoxin-induced pulmonary dysfunctions is prevented by C1- esterase
inhibitor. J. Clin Invest. 1993; 91: 2754-2760.
18. Warr TA, Rao LVM, Rapaport SI. Human plasma extrinsic pathway
inhibitor activity: II. Plasma levels in disseminated intravascular
coagulation and hepatocellular disease. Blood 1989; 74: 994-998.
19. Gando S, Nakanishi Y, Kameue T, Nanzaki S. Soluble trombomodulin increases in patients with disseminated intravascular coagulation and in those with multiple organ disfunction syndrome after trauma: Role of neutrophil elastase. J. Trauma. 1995; 39: 660-664.
20. Rapaport S. The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation. Thromb Hemostas. 1991; 66: 6-15.
21. Esmon CT, Taylor FB, Snow TR. Inflammation and coagulation: linked processes potentially regulated throug a common pathaway mediated by Protein C. Thromb Haemostas. 1991; 66: 160-165.
22. Klebanoff SJ. Phagocytic cells: products of oxygen metabolism. In: Gallin JL, Goldstein IM, Snyderman R Eds. Inflammation: basic principles and
clinical correlates. New York Raven Press. 1988: 391-444.
23. Grisham MB, Jefferson MM, Melton DF, Thomas EL. Chlorination of
endogenous amines by isolated neutrophils: ammonia-dependent bactericidal, cytotoxic, and cytolitic activities of the chloramines. J Biol Chem. 1984; 259: 10404-1413.
24. Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. Br Med J. 1996: 312: 683-687.
25. Campbell EJ, Campbell MA. Pericellular proteolysis by neutrophils in the presence of proteinase inhibitors: effects of sustrate opsonization. J Cell Biol. 1988; 106: 667-676.
26. Baker WF. Clinical aspects of disseminated intravascular coagulation: A clinician’s point of view. Semin Thromb Hemost 1989; 15: 1-13.
27. Bick RL: Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemost 1988; 14: 299-310.
28. Bick RL, Baker WF. Disseminated intravascular coagulation. Hematol Patol 1992; 6: 1-24.
29. Pasquini E, Gianni L. Aitini E, Nicolini M, Fattori PO, Cazzini G, et al.
Acute disseminated intravascular coagulation syndrome in cancer patients.
Oncology 1995; 52: 505-508.
30. Prentice CR. Acquired coagulations disorders. Clin Hematol 1985; 14:
413-442.
31. Baron JM, Baron BW. Bleeding disorders. In: Hall JB, Schmidt GA, Wood LDH. Eds. Principles of critical care. 1.ª ed. New York. Mc Graw-Hill. 1992; 1818-1831.
32. Jones DK, Luddington R, Higenbottam TW, Scott J, Cavarocchi N,
Reardon D, et al. Changes in factor VIII proteins after cardiopulmonary
bypass in man suggest endothelial damage. Thromb Haemostas. 1988; 60: 199-204.
33. Woodman RC, Harker LA. Bleeding complications associated with
cardiopulmonary bypass. Blood 1990: 76: 1680-1697.
34. Gando S, Tedo I, Kubota M. Posttrauma coagulation and fibrinolysis. Crit Car Med. 1992; 20: 594-600.
35. Castro MA, Goodwin TM, Shaw KJ, Ouzounian JG, McGehee WG.
Disseminated intravascular coagulation and antithrombin-III depression
in acute fatty liver of pregnancy. Am J Obstet Gynecol. 1996: 174: 211-216.
36. Richey ME, Gilstrap LC, Ramin SM. Management of disseminated
intravascular coagulopathy. Clin Obstet Gynecol. 1995; 38: 514-520.
37. Finley BE. Acute coagulopathy in pregnancy. Med Clin North Am. 1989; 73: 723-743.
38. Capon SM; Goldfinger D. Acute hemolytic transfusion reaction, a
paradigm of the systemic inflammatory response: new insights into
pathophysiology and treatment. Transfusion 1995; 35: 513-520.
39. Fink MP. Lipid mediators in critical care medicine. In Chernow B Ed. The pharmacology approach to the critically ill patient. 3.º ed. Baltimore (Ma). Williams& Wilkins. 1994: 875-889.
40. Katsumura Y, Ohtsubo K. Incidence of pulmonary thromboembolism,
infarction and haemorrage in disseminated intravascular coagulation: a necroscopic analysis. Thorax. 1995; 50: 160-164.
41. Robboy SJ, Major MC, Colman RW, Minna JD. Pathology of
disseminated intravascular coagulation (DIC) Analysis of 26 cases. Human
Pathol 1972; 3: 327-337.
42. Colman RW. The role of plasma proteases in septic shock. N Eng J Med. 1989, 320: 1207-1209.
43. Levi M, ten Cate H, van der Poll T, van Deventer S.J. Pathogenesis of
disseminated intravascular coagulation in sepsis. JAMA. 1993; 270: 975-
979.
44. Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983; 72: 1672-1677.
45. Colman RW. Contact system in infectious disease. Rev Infect Dis. 1989; 2: S689-S699.
46. Warr TA, Rao WM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489.
47. Bone RC. Modulators of coagulation: A critical appraisal of their role in sepsis. Arch Intern Med. 1992; 152:1381-1389.
48. Collins PW, Noble KE, Reittie JR, Hoffbrand AV, Pasi KJ, Yong KL. Induction of tissue expression in human monocyte/endothelium cocultures. Br J Hematol. 1995; 91: 963-970.
49. Butcher DC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991; 67:1033-1036.
50. Arditi M, Zhou J, Dorio R, Rong GW, Goyert SM, Kim KS. Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14. Infect Immun 1993; 61: 3149-3156.
51. Ward PA, Mulligan MS, Varpociyan AA. Endothelial and leukocytic
adhesion molecules in the pathogenesis of acute pulmonary injury. Thromb
Haemostas 1993; 70: 155-157.
52. Mulligan MS, Varani J, Dame MK, Lane CN, Smith CW, Anderson
DC, et al. Role of endothelial- leukocyte adhesion molecule 1 (ELAM-1)
in neutrophil-mediated lung injury in rats. J Clin Invest. 1991; 88:
1396-1406.
53. Mulligan MS, Polley MJ, Bayer RJ, Nunn MF, Paulson JC, Ward PA.
Neutrophil-dependent acute lung injury: requirement for P-selectin
(GMP-140). J Clin Invest 1992; 90: 1600-1607.
54. Smith CW, Kishimoto TK, Abbassi O, Hughes B, Rothlein R, McIntire LV. et al. Chemotactic factors regulate lectin adhesion molecule 1
(LECAM-1) dependent neutrophil adhesion to cytokines-stimulated
endothelial cells in vitro. J Clin Invest. 1991; 87: 609-618.
55. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium: effects on tissue-type
plasminogen activator and type I plasminogen activator inhibitor. J Biol Chem. 1988; 263: 5797-5803.
56. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent
inhibition of plasminogen activation after administration of intravenous
endotoxin to normal subjects. N Eng J Med. 1989; 320:1165-1172.
57. Gando S, Nakanishi Y, Tedo I. Cytokines and plasminogen activator
inhibitor-1 in posttrauma disseminated intravascular coagulation:
Relationship to multiple organ dysfunction syndrome. Crit Care Med. 1995; 23: 1835-1842.
58. Páramo JA, Fernádez FJ, Rocha E. Plasminogen activator inhibitor activity in bacterial infection. Thromb Haemostas 1988; 59: 451-454.
59. Waage A, Steinshamn S. Cytokine mediators of septic infections in the
normal and granulocytopenic host. Eur J Haematol. 1993; 50: 243-249.
60. Heflin C; Brigham K. Prevention by granulocyte depletion of increased
vascular permeability of sheep lung following endotoxemia. J Clin Invest.
1981; 68: 1253-1260.
61. Windsor ACJ, Mullen PG, Fowler AA, Sugerman HJ. Role of the neutrophil in adult respiratory distress syndrome. Br J Surg 1993; 80: 10-17.
62. Thijs LG, Hack CE.The course of cytokines levels in sepsis. Intens Care Med. 1995; 21: S258-S263.
63. van der Poll T, Buller HR, ten Cate H, Wortel C, Bauer KA, van Daventer JH. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Eng J Med. 1990; 322: 1622-1627.
64. Gimbrone MA Jr, Brock AF, Schafer AI. Leukotriene 4 stimulates
polymorphonuclear leukocytes adhesion to cultured vascular endothelial
cells. J Clin Invest 1984; 74: 1552-1555.
65. Burgess CA, McCandless BK, Cooper JA, Malik AB. Leukotriene 4
increases pulmonary transvascular filtration by a neutrophil-independent
mechanism. J Appl Physiol 1990; 68: 1260-1264.
66. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989; 320: 363-376.
67. Anderson BO, Brown JM, Harken AH. Mechanisms of neutrophil
mediated tissue injury. J Surg Res. 1991; 51: 170-179.
68. Giroir PB. Mediators of septic shock: New approaches for interruption the endogenous inflammatory cascade. Crit Car Med. 1993; 21: 70-79.
69. Brigham KL, Meyrick B, Berry LJ, Repine JE. Antioxidants protect
cultured bovine lung endothelial cells from injury by endotoxin. J Appl
Physiol. 1987; 63: 840-850.
70. Harlan JM, Harker LA, Reidy MA; Gajdusek GM, Schwartz SM, Striker GE. Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab Invest. 1983; 48: 269-274.
71. Meyrick B, Ryan US, Brigham KL. Direct effects of E Coli endotoxin on structure and permeability of pulmonary endothelial monlayers and the
endothelial layer of intimal explants. Am J Pathol. 1986; 122: 140-151.
72. Meyrick B. Endotoxin-mediated pulmonary endothelal cell injury. Fed
Proc 1986; 45: 19-24.
73. Thijs LG, de Boer JP, de Groot MC, Hack CE. Coagulation disorders in septic shock. Intens Care Med 1993; 19: S8-S15.
74. Siebeck M, Pink E, Weipert J, Jochun M, Fritz H, Spagnnalg M, et al.
Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock.
J Trauma. 1993; 34: 193-198.
75. Martínez-Brotons F, Oncins J, Mestres J, Amargos V, Reynaldo C. Plasma Kallikrein-Kinin sytem in patients with uncomplicated sepsis and septic shock. Comparison with cardiogenic shock. Thromb Haemostas. 1987; 58: 709-713.
76. Asakura H, Kamikubo Y, Goto A, Shiratori Y, Yamazaki Y, Jokaji H et al. Role of tissue factor in disseminated intravascular coagulation. Thromb
Res. 1995; 80: 217-224.
77. Stern D, Nawroth P, Handley D. An endothelial cell-dependent pathway coagulation. Proc Natl Acad Sci USA. 1985; 82: 2523-251.
78. Bick RL. Platelet function defects: A clinical review. Sem Thromb
Hemostas. 1992; 18: 167-184.
79. Vaziri DN, Toohey J, Powers D. Activation of intrinsic coagulation pathway in pre-eclampsia. Am J Med. 1986; 80: 103-109.
80. Hayakawa M, Maki M. Coagulation-fibrinolyic and kinin-forming
systems in toxemia and pregnancy. Gynecol Obstet Invest. 1988; 26:
181-191.
81. Carvalho AC, Saullo VJ, Bellman SM, Quinn D, Zapol WM.
Intravascular coagulation in acute respiratory failure. Circulation 1982;
66: 45-54.
82. Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest 1987; 79: 1874-1878.
83. Carr JM. Disseminated intravascular coagulation in cirrhosis. Hepatology. 1989; 10: 103-111.
84. Carr JM, McKinney M, McDonagh J. Diagnosis of DIC: Role of D-Dimer. Am J Clin Pathol. 1989; 91: 280-288.
85. Paramo JA, Rifon J, Fernandez J. Thrombin activation and increased
fibrinolysis in patients with chronic liver disease. Blood Coag Fibrinol.
1991; 2: 227-234.
86. Pelzer H, Schwartz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked
immunosorbent assay. Sem Thromb Haemostas. 1988; 59: 101-106.
87. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Cytokines, soluble
thrombomodulin and disseminated intravascular coagulation in patients
with systemic inflamatory response syndrome. Thromb Res. 1995; 80:
519-526.
88. Hesselvik JF, Blomback M, Brodin B, Maller R. Coagulation, fibrinolysis and kallikrein systems in sepsis: relation to outcome. Crit Care Med. 1989; 17: 724-733.
89. Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res. 1995; 80: 339-348.
90. Schuster H.P. AT-III in septicemia with DIC. Intens Care Med. 1993; 19: S16-S18.
91. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock multiple organ failure and disseminated intravascular
coagulation. Compared pattern of Antithrombin III, Protein C, and Protein S deficiencies. Chest 1992; 101: 816-823.
92. Lamy M, Deby-Dupont G. Is sepsis a mediator-inhibitor mismatch?.
Intens Care Med. 1995; 21: S250-S257.
93. Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, et al. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemostas 1991; 65: 291-295.
94. Stump DC, Taylor FB, Neshein ME, Giles AR, Dzik WH, Bovill EG.
Pathologic fibrinolysis as a cause of clinical bleeding. Sem Thromb
Hemostas. 1990; 16: 260-273.
95. Pesola GR, Carlon GC. Pulmonary embolus-induced disseminated
intravascular coagulation. Crit Care Med. 1987; 15: 983-984.
96. Fallat RJ, Mielke CH, Rodvien R. Adult respiratory distress syndrome and gram-negative sepsis. Arch Intern Med 1980; 140: 612-613.
97. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med. 1982; 3: 35-56.
98. Raffin TA. Novel approaches to ARDS and sepsis. In: Chernow B,
Shoemaker WC Eds. Critical Care State of Art. Fullarton CA. The Society
of Critical Care Medicine. 1980: 247-280.
99. Maunder RJ, Harlan JM, Pepe PE, Paskell S, Carrico CJ, and Hudson LD. Measurement of plasma fibronectin in patients who develop the adult respiratory distress syndrome. J Lab Clin Med. 1984; 104: 583-590.
100. St John RC, Dorinsky PM. Immunologic therapy for ARDS, septic shock, and multiple-organ-failure. Chest 1993; 103: 932-943.
101. Lorente JA, Garcia-Frade LJ, Landin L, de Pablo R, Torrado C, Renes E, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993; 103: 1536-1542.
102. Ono S, Mochizuki H, Tamakuma S. A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Am J Surg 1996; 171: 409-415.
103. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Haemostas 1995; 74: 848-852.
104. Sala N, Fontcuberta J, Rutllan ML. New biological concepts on
coagulation inhibitors. Intens Care Med. 1993; 19: S3-S7.
105. Lachmann PJ. Biological functions of the complement system. Biochem Soc Trans. 1990; 18: 1143-1145.
106. Weinberg PF, Matthay MA, Webster RO, Noskos KV, Goldstein IM, Murray JF. Biologically active products of complement and acute lung
injury in patients with the sepsis syndrome. Am Rev Respir Dis. 1984;
130: 791-796.
107. de Boer JP, Wolbink GJ, Thijs LG, Baars JW, Wagstaff J, Hack CE. Interplay of complement and cytokines in the pathogenesis of septic shock. Immunopharmacology 1992; 24: 135-148.
108. Robbins RA, Russ WD, Rasmussen JK, Clayton MM. Activation of the complement system in the adult respiratory distress syndrome. Am Rev
Respir Dis. 1987; 135: 651-658.
109. Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Study of two parameters: thrombin-antitrhombin III complex and D-Dimers. Gynecol Obstet Invest. 1987; 24: 170-178.
110. Castillo R. Hipocoagulabilidades adquiridas. Síndrome de la coagulación intravascular diseminada (CID). Deficiencias complejas de la hemostasia. En: Sans-Sabrafen J ed. Hematología Clínica 3.ª ed. Barcelona. Ed Mosby/Doyma. 1994; pp 533-548.
111. Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, et al. Increased plasma-soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol. 1996; 51: 255-260.
112. Oguma Y, Sakuragawa N, Maki M. Treatment of disseminated
intravascular coagulation with low molecular weigth heparin. Semin
Thromb Hemost. 1990; 16 (sup): 34-39.
113. Ziegler E, McCutchan J, Fierrer J, Glauser MP, Sadoff JC, Douglas H, et al. Prevention of death from Gram-negative bacteremia and shock with
human antiserum to a mutant Escherichia coli. N Engl J Med. 1982; 307:
1225-1231.
114. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE et al. Prevention of death fron gram negative bacteremia and sepsis by HA-1A a human monoclonal antibody specific for lipid A of endotoxin. Results of phase III trial. Clin Res 1990; 38: 304A.
115. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR,Emmanel GE et al. A controlled clinical trial of E5 murine monoclonal
antibody to endotoxin in the treatment of gram-negative sepsis. JAMA.
1991; 266: 1097-1102.
116. Opal SM, Cross AS, Sadoff JC, Kelly NM, Bodmer MW, Palardy JE, et al. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor
monoclonal antibodies in a neutropenic rat model of pseudomonas sepsis.
J Clin Invest 1991; 88: 885-890.
117. Taylor FB, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S and Blick KE. Protein C prevents the coagulopathic and lethal effects of
escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
118. Bone RC. Gram-negative sepsis: a dilem of modern medicine. Clin
Microbiol Rev. 1993; 6: 57-68.
119. Toth PD, Mikulaschek AW. Effects of a platelet-activating factor
antagonist, CV-3988, on different shock model in the rat. Circ Shock.
1986; 20: 193-203.
120. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575.
121. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, et al. Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Car Med. 1993; 21: 318-327.
122. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor IgG heavy chain chimeric protein as a bivalent antagonist of TNF
activity. J Exp Med 1991; 174: 1483-1489.
123. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC.
Interleukyn-1 receptor antagonist reduces mortality from endotoxin shock.
Nature. 1990; 348: 550.552.
124. Dinarello CA, Thompson RC. Blocking IL-1: interleukyn-1 receptor
antagonist activity in vivo and in vitro. Immunol Today. 1991; 12: 404-
409.
125. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed
mechanisms of pathogenesis. Ann Intern Med. 1994; 120: 771-783.
126. Pennington JE. Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 1993; 17: S515-S519.
127. Creasey AA, Chang ACK, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from escherichia coli septic shock. J Clin Invest. 1993; 91: 2850-2860.
128. Feinstein D. Diagnosis and management of disseminated intravascular
coagulation: The role of heparin therapy. Blood. 1982; 60: 284-287.
129. Tazawa S, Ichikawa K, Misawa K, Fukuyama J, Hamano S, Miyata H, et al. Effects of low molecular weight heparin on a severely antithrombin
III-decreased disseminated intravascular coagulation model in rabbits.
Thrombos Res. 1995; 80:391-198.
130. Bone RC. A critical evaluation of new agents for the treatment of sepsis. JAMA 1991; 266: 1686-1691.
131. Bolan CD, Alving BM. Pharmacologic agents in the management of
bleeding disorders. Transfusion. 1990; 30: 541-551.
132. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H et al. Activated protein C attenuates endotoxin-induced pulmonary vascular
injury by inhibiting activated leukocytes in rats. Blood. 996; 87: 642-647.
133. Harper P. The clinical use of antithrombin concentate in septicaemia. Br J Hosp Med. 1994; 52: 571-574.
134. Vinazzer H. Clinical use of antithrombin III concentrates. Vox Sang. 1987; 53: 193-198.
135. Eidelman LA, Pizov R, Sprung CL. New therapeutic approaches in sepsis: a critical review. Intens Care Med. 1995; 21: S269-S272.
136. Fourrier F, Jourdain M, Tournois A, Caron C, Goudemand J, Chopin C. Coagulation inhibitor substitution during sepsis. Intens Car Med. 1995; 21: S264-S268.
137. Fourrier F, Chopin C, Huart J.J, Runge I, Caron C, Goudemand J. Double-blind placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-888.
138. Mammen EF. Perspectives for the future. Intens Care Med. 1993; 19: S29-S34.
139. Hack CE, Ogilvie AC, Eisele B, Eeremberg AJM, Wagstaff J, Thijs GL. C1-inhibitor substitution therapy in septic shock and in the vascular leak
syndrome induced by high doses of interleukin-2. Intens Care Med 1993;
19: S19-S28.
140. Hack CE. Inhibitor substitution in sepsis. Intens Care Med 1993; 19:
S1-S2.
141. Hardaway RM, Williams CH, Marvasti M, Farias M, Tseng A, Pinon I, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Car Med 1990; 18: 1413-1418.
142. Hardaway RM, Williams CH. Prevention of multiple organ failure with plasminogen activator. Curr Ther Res. 1991; 49: 711-722.
143. Humphries J.E. Transfusion therapy in acquired coagulopathies. Hematol/Oncol Clin North Am. 1994; 8: 1181-1201.
144. Stehling L, Luban NLC, Anderson KC, Sayers MH, Long A, Attar S, et al. Guidelines for blood utilization review. Transfusion. 1994; 34: 438-448.
145. Tulis JL, Alving B. Fresh-frozen plasma. Indications and risk. Consensus conference. JAMA. 1985; 253: 551-553.
146. Consensus Conference. Platelet transfusion therapy. JAMA 1987; 257: 1777-1780.
147. Audet AM, Goodnough LT. Practice strategies for elective red blood cell transfusion. Ann Intern Med. 1992; 116: 403-406.
148. Maruyama I. Therapeutic evaluation of recombinant thrombomodulin.
Jpn J Clin Med. 1992; 50: 2561-2566.